87 related articles for article (PubMed ID: 2013037)
1. Soluble histocompatibility antigen class I in breast cancer patients in relation to tumor burden.
Klein B; Klein T; Figer A; Bleiberg M; Shapira J; Loven D; Livni E; Lurie H; Niska A
Cancer; 1991 May; 67(9):2295-9. PubMed ID: 2013037
[TBL] [Abstract][Full Text] [Related]
2. Correlation between tumour and serum beta 2m expression in patients with breast cancer.
Klein T; Levin I; Niska A; Koren R; Gal R; Schachter J; Kfir B; Narinski R; Warchaizer S; Klein B
Eur J Immunogenet; 1996 Dec; 23(6):417-23. PubMed ID: 8971539
[TBL] [Abstract][Full Text] [Related]
3. Serum intracellular adhesion molecule-1 (sicam-1) and soluble hla class-1 antigens in breast-cancer patients in relation to tumor burden.
Levin I; Klein T; Shapira Y; Lurie H; Kfir B; Narinsky R; Lehmann J; Klein B
Oncol Rep; 1994 Jan; 1(1):217-20. PubMed ID: 21607340
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of soluble HLA class I heterodimers and beta 2-microglobulin in patients with active pulmonary tuberculosis.
Inostroza J; Muñoz P; Espinoza R; Millaqueo L; Diaz P; Leiva L; Sorensen R
Hum Immunol; 1994 Jul; 40(3):179-82. PubMed ID: 7960960
[TBL] [Abstract][Full Text] [Related]
5. Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.
Wintzer HO; Benzing M; von Kleist S
Br J Cancer; 1990 Aug; 62(2):289-95. PubMed ID: 2201398
[TBL] [Abstract][Full Text] [Related]
6. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer.
Bhan AK; DesMarais CL
J Natl Cancer Inst; 1983 Sep; 71(3):507-16. PubMed ID: 6193308
[TBL] [Abstract][Full Text] [Related]
7. The significance of soluble interleukin-2, soluble interleukin-2 receptors, soluble ICAM-1 and beta 2-microglobulin in breast cancer patients.
Klein B; Levin I; Kfir B; Mishaeli M; Shapira J; Klein T
Tumour Biol; 1995; 16(5):290-6. PubMed ID: 7652467
[TBL] [Abstract][Full Text] [Related]
8. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia.
Di Giovanni S; Valentini G; Carducci P; Giallonardo P
Acta Haematol; 1989; 81(4):181-5. PubMed ID: 2502891
[TBL] [Abstract][Full Text] [Related]
9. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
10. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer.
Kaklamanis L; Leek R; Koukourakis M; Gatter KC; Harris AL
Cancer Res; 1995 Nov; 55(22):5191-4. PubMed ID: 7585572
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.
Litam P; Swan F; Cabanillas F; Tucker SL; McLaughlin P; Hagemeister FB; Rodriguez MA; Velasquez WS
Ann Intern Med; 1991 May; 114(10):855-60. PubMed ID: 2014946
[TBL] [Abstract][Full Text] [Related]
12. Enhanced expression in vivo of HLA-ABC antigens and beta 2-microglobulin on human lymphoid cells induced by human interferon-alpha in patients with lung cancer. Enhanced expression of class I major histocompatibility antigens prior to treatment.
Nissen MH; Plesner T; Larsen JK; Olesen BK; Ernst P
Clin Exp Immunol; 1985 Feb; 59(2):327-35. PubMed ID: 2983911
[TBL] [Abstract][Full Text] [Related]
13. Elevated pretreatment levels of soluble CD8 and Beta-2-microglobulin as indicators of relapse in breast-cancer patients.
Klein B; Levin I; Lurie H; Nyska A; Shapira J; Kravits M; Klein T
Int J Oncol; 1994 Feb; 4(2):471-4. PubMed ID: 21566948
[TBL] [Abstract][Full Text] [Related]
14. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.
Swan F; Velasquez WS; Tucker S; Redman JR; Rodriguez MA; McLaughlin P; Hagemeister FB; Cabanillas F
J Clin Oncol; 1989 Oct; 7(10):1518-27. PubMed ID: 2674337
[TBL] [Abstract][Full Text] [Related]
15. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
[TBL] [Abstract][Full Text] [Related]
16. Expression of beta-2-microglobulin by nasopharyngeal carcinoma.
Shiu W; Leung SF; Leung WT; Ho S; Tao M
Br J Cancer; 1992 Sep; 66(3):555-7. PubMed ID: 1520593
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma.
Vangangelt KMH; van Pelt GW; Engels CC; Putter H; Liefers GJ; Smit VTHBM; Tollenaar RAEM; Kuppen PJK; Mesker WE
Breast Cancer Res Treat; 2018 Apr; 168(3):601-612. PubMed ID: 29273955
[TBL] [Abstract][Full Text] [Related]
18. Beta 2-microglobulin and its binding activity in serum from patients with SLE.
Evrin PE; Ström T
Ann Rheum Dis; 1984 Apr; 43(2):267-74. PubMed ID: 6370153
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
20. Prediction of clinical course and recurrence of human ovarian cancer by several serum tumor markers.
Kikuchi Y; Kita T; Iwano I; Kuki E; Oomori K; Kizawa I
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):69-76. PubMed ID: 2926196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
